{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T12:04:04Z","timestamp":1725105844054},"reference-count":10,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,10]],"date-time":"2005-03-10T00:00:00Z","timestamp":1110412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background.\u2002\u2002<\/jats:bold> Carbonic anhydrase inhibitors have been successfully used to treat peptic ulcers. Although carbonic anhydrase restriction does not inhibit <jats:italic>Helicobacter\u00a0pylori<\/jats:italic> in vitro, recent studies suggest that carbonic anhydrase inhibition reduces the ability of <jats:italic>H.\u00a0pylori<\/jats:italic> to survive in an acid environment as present in the stomach.<\/jats:p><jats:p><jats:bold>Methods.\u2002\u2002<\/jats:bold> In a pilot study, we examined the effect of acetazolamide 500\u00a0mg as twice a day for 4\u00a0days in volunteers with active <jats:italic>H.\u00a0pylori<\/jats:italic> infection. Effectiveness was judged by changes in the results of the urea breath test.<\/jats:p><jats:p><jats:bold>Results.\u2002\u2002<\/jats:bold> Eight <jats:italic>H.\u00a0pylori<\/jats:italic> infected volunteers completed the test. No urea breath test reverted to negative and there was a trend for the urea breath test value to increase [e.g. delta over baseline (DOB) mean \u00b1 SE increased from 50.9\u00a0\u00b1\u00a013 at baseline to 64.9\u00a0\u00b1\u00a013 at day 5] during treatment with acetazolamide.<\/jats:p><jats:p><jats:bold>Conclusion.\u2002\u2002<\/jats:bold> The potential effect of carbonic anhydrase inhibitors on acid secretion may prevent effect on <jats:italic>H.\u00a0pylori<\/jats:italic> in vivo and\/or the sites of infection at the surface of the stomach may have a pH higher for any postulated acid\u2010dependent effect to have an effect clinically.<\/jats:p>","DOI":"10.1111\/j.1523-5378.2005.00306.x","type":"journal-article","created":{"date-parts":[[2005,3,10]],"date-time":"2005-03-10T20:26:58Z","timestamp":1110486418000},"page":"136-138","source":"Crossref","is-referenced-by-count":18,"title":["Effect of the Carbonic Anhydrase Inhibitor, Acetazolamide, on <i>Helicobacter pylori<\/i> Infection in vivo: A Pilot Study"],"prefix":"10.1111","volume":"10","author":[{"given":"Rassa","family":"Shahidzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antone","family":"Opekun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Shiotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.4.599"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.022111"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34218"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-9639(02)00467-3"},{"key":"e_1_2_6_6_2","first-page":"A402","article-title":"The H. pylori periplasmic alpha\u2010carbonic anhydrase is required for acid survival","volume":"126","author":"Scott DR","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4838(89)90141-6"},{"key":"e_1_2_6_8_2","first-page":"93","article-title":"Carbonic anhydrase inhibitors in the treatment of gastro\u2010duodenal ulcer","volume":"30","author":"Puscas D","year":"1975","journal-title":"GEN"},{"key":"e_1_2_6_9_2","first-page":"233","article-title":"In vivo susceptibility of Campylobacter pylori","volume":"84","author":"Graham DY","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_10_2","first-page":"1158","article-title":"Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin","volume":"86","author":"Graham DY","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1083-4389.2004.00191.x"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1523-5378.2005.00306.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1523-5378.2005.00306.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T02:48:28Z","timestamp":1697078908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1523-5378.2005.00306.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,10]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1523-5378.2005.00306.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-5378.2005.00306.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,10]]}}}